AVR supply chain intelligence for Anteris Technologies Global Corp.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Anteris Technologies Global Corp. (AVR) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| NORTHCROSS-WEST-INDUSTRIAL-OWNER-LLC | NORTHCROSS-WEST-INDUSTRIAL-OWNER-LLC | 92% | The Lease has an initial term commencing September 1, 2026 and expiring August 31, 2037 and may be extended for two periods of 84 months each at market rent, subject to other terms and conditions set… |
| TD-SECURITIES-USA-LLC | TD-SECURITIES-USA-LLC | 92% | Pursuant to the terms of the Agreement, the Company may offer and sell through TD Cowen, from time to time and at its sole discretion, shares of the Company’s common stock |
| V2VMEDTECH-INC | V2VMEDTECH-INC | 90% | The Company is required to pay a break fee of $400,000 to v2v, which will be used by v2v for continued development of the technology. |
| EW | Edwards Lifesciences Corporation | 72% | market, and in particular the TAVR market. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. Our products face a mix of co… |
| EW | Edwards Lifesciences Corporation | 72% | Reciprocal relationship from EW graph: Reciprocal relationship from AVR graph: market, and in particular the TAVR market. These markets are characterized by rapid change resulting from technological … |
| ITGR | Integer Holdings Corporation | 72% | Reciprocal relationship from ITGR graph: Reciprocal relationship from AVR graph: he development project, and therefore the agreement, was terminated on February 11, 2025. We did not receive any reven… |
| ITGR | Integer Holdings Corporation | 72% | he development project, and therefore the agreement, was terminated on February 11, 2025. We did not receive any revenue from ESIA pursuant to the ESIA Agreement. As of December 31, 2024, we paid an … |
| LMAT | LeMaitre Vascular, Inc. | 72% | ment No. 2 to Transition Services Agreement, dated December 19, 2022, among Anteris Technologies Ltd, Admedus Regen Pty Ltd, Admedus Biomanufacturing Pty Ltd and LeMaitre Vascular, Inc. S-1 11/22/202… |
| LMAT | LeMaitre Vascular, Inc. | 72% | Reciprocal relationship from LMAT graph: Reciprocal relationship from AVR graph: ment No. 2 to Transition Services Agreement, dated December 19, 2022, among Anteris Technologies Ltd, Admedus Regen Pt… |
| MDT | Medtronic plc | 72% | Reciprocal relationship from MDT graph: Reciprocal relationship from AVR graph: Reciprocal relationship from MDT graph: Reciprocal relationship from AVR graph: market, and in particular the TAVR mark… |
| MDT | Medtronic plc | 72% | market, and in particular the TAVR market. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. Our products face a mix of co… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| 4C-MEDICAL-TECHNOLOGIES-INC | 4C-MEDICAL-TECHNOLOGIES-INC | 90% | The Supply and License Agreement with 4C (the "4C Agreement"), had an initial seven-year term that ended on June 1, 2025, and under its terms would automatically renew for successive one-year periods… |
| LEMAITRE-VASCULAR-INC | LEMAITRE-VASCULAR-INC | 90% | Such sales have historically been made principally to 4C Medical Technologies, Inc. ("4C") and, in prior periods, to LeMaitre Vascular, Inc. ("LeMaitre"), a distributor of medical products. |
| LMAT | LeMaitre Vascular, Inc. | 85% | s determined that the activities of the business as reviewed by our Vice Chairman and Chief Executive Officer, who also serves as our chief operating decision maker, are one segment, being the develo… |
| LMAT | LeMaitre Vascular, Inc. | 85% | Reciprocal relationship from LMAT graph: Reciprocal relationship from AVR graph: s determined that the activities of the business as reviewed by our Vice Chairman and Chief Executive Officer, who als… |
| MEDICAL-TECHNOLOGIES-INC | MEDICAL-TECHNOLOGIES-INC | 85% | s determined that the activities of the business as reviewed by our Vice Chairman and Chief Executive Officer, who also serves as our chief operating decision maker, are one segment, being the develo… |
| EW | Edwards Lifesciences Corporation | 72% | Reciprocal relationship from EW graph: Reciprocal relationship from AVR graph: market, and in particular the TAVR market. These markets are characterized by rapid change resulting from technological … |
| EW | Edwards Lifesciences Corporation | 72% | market, and in particular the TAVR market. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. Our products face a mix of co… |
| ITGR | Integer Holdings Corporation | 72% | Reciprocal relationship from ITGR graph: Reciprocal relationship from AVR graph: he development project, and therefore the agreement, was terminated on February 11, 2025. We did not receive any reven… |
| ITGR | Integer Holdings Corporation | 72% | he development project, and therefore the agreement, was terminated on February 11, 2025. We did not receive any revenue from ESIA pursuant to the ESIA Agreement. As of December 31, 2024, we paid an … |
| MDT | Medtronic plc | 72% | market, and in particular the TAVR market. These markets are characterized by rapid change resulting from technological advances, innovations and scientific discoveries. Our products face a mix of co… |
| MDT | Medtronic plc | 72% | Reciprocal relationship from MDT graph: Reciprocal relationship from AVR graph: n as of December 31, 2025, and $ 0.2 million as of December 31, 2024. 104 Table of Contents ANTERIS TECHNOLOGIES GLOBAL… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| AVR-DEBT-13803 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2025-12-31. |
| AVR-DEBT | Debt stack $3.7M | 90% | Market cache reports total debt of $3.7M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| AVR-OWNER-L1-CAPITAL-PTY-LTD | L1 Capital Pty Ltd | 90% | 13F overlay lists L1 Capital Pty Ltd as top holder; 129 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| ITGR | Integer Holdings Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| LMAT | LeMaitre Vascular, Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| MDT | Medtronic plc | 100.00 | 1 | ['customer', 'supplier'] |
| EW | Edwards Lifesciences Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| ALC | Alcon Inc. | 50.00 | 2 | |
| ABT | Abbott Laboratories | 50.00 | 2 | |
| DXCM | DexCom, Inc. | 50.00 | 2 | |
| SIBN | SI-BONE, Inc. | 50.00 | 2 | |
| ELUT | Elutia Inc. | 50.00 | 2 | |
| GWW | W.W. Grainger, Inc. | 50.00 | 2 | |
| KIDS | OrthoPediatrics Corp. | 50.00 | 2 | |
| ISRG | Intuitive Surgical, Inc. | 50.00 | 2 | |
| LIVN | LivaNova PLC | 50.00 | 2 | |
| MASI | Masimo Corporation | 50.00 | 2 | |
| MBAI | Check-Cap Ltd. | 50.00 | 2 | |
| SSII | SS Innovations International, Inc. | 50.00 | 2 | |
| RBOT | Vicarious Surgical Inc. | 50.00 | 2 | |
| MOVE | Corvex Inc. | 50.00 | 2 | |
| SNN | Smith & Nephew plc | 50.00 | 2 | |
| PYPD | PolyPid Ltd. | 50.00 | 2 |